Q BioMed Inc. Appoints Industry Executive to Management Team

Company welcomes David Laskow-Pooley, former GSK, Abbott, Amersham executive to its management team

Dec 16, 2015, 09:46 ET from Q BioMed Inc

NEW YORK, December 16, 2015 /PRNewswire/ --

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to welcome David Laskow-Pooley to the Q Team as VP Scientific & Product Development.

Mr. Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics.

Denis Corin CEO of Q BioMed stated, "We are very pleased to officially welcome David to the Q Team. David has kindly been providing a sounding board for many of the technologies we have been vetting over the last several months and we are excited to now have him formally on board and look forward to taking advantage of his vast experience as we grow a pipeline of innovative technologies."

David Laskow-Pooley said, "I am excited to join Q BioMed and have been impressed with the caliber of the people, advisory groups and the potential of the products already in the pipeline and those on the 'workbench' including diagnostics, orphan drugs, rare pediatric diseases and rare tropical diseases. I really like the business plan and the opportunity it presents and I look forward to contributing in any way I can."

David, a Pharmacist by profession, founded Pharmafor ltd, a company providing specialist assistance to small and emerging enterprises in the medical technology sector. Having been responsible for and involved in several successful spin-outs and start-ups he now focuses this knowledge and experience into assisting a portfolio of start-ups and growth companies. David is a non-executive director and Chair of OBN Ltd, a highly successful trade association for SME enterprises in the Life Sciences sector. Additionally, he is a non-executive director of TapImmune Inc, an immunotherapeutic vaccine company in the oncology sector.

About Q BioMed Inc. 

Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need‏.

Forward-Looking Statements: 

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


Denis Corin
Q BioMed Inc.